«

»

Biosimilar drugs often translate to lower provider profits, says Navigant analysis

One of the main culprits is the "buy-and-bill" reimbursement model for infused therapies.

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive